所有图片(1)

文件

U0100000

尿嘧啶1-β-D-阿拉伯呋喃糖苷

Name: 尿嘧啶1-β-<SC>D</SC>-阿拉伯呋喃糖苷
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

1-β-D-阿拉伯呋喃糖尿嘧啶

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₉H₁₂N₂O₆

CAS号:

3083-77-0

分子量:

244.20

Beilstein:

28749

MDL编号:

MFCD00065998

UNSPSC代码:

41116107

PubChem化学物质编号:

329827589

NACRES:

NA.24

等级

pharmaceutical primary standard

API类

uracil arabinoside

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N2C=CC(=O)NC2=O

InChI

1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)/t4-,6-,7+,8-/m1/s1

InChI key

DRTQHJPVMGBUCF-CCXZUQQUSA-N

正在寻找类似产品? 访问产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Uracil arabinoside EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Toxicology. 'Humanized' mouse detects deadly drug side effects.

Jon Cohen

Science (New York, N.Y.), 344(6181), 244-245 (2014-04-20)

Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.

Ju-Yeon Cho et al.

Gut, 63(12), 1943-1950 (2014-03-13)

It is generally stated that oral antiviral therapy in patients with chronic hepatitis B (CHB) decreases the risk of developing hepatocellular carcinoma (HCC). Although oral nucleos(t)ide analogues (NUCs) may induce a state similar to inactive stage CHB, the long-term risk

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件